OncoMatch/Clinical Trials/NCT06673017
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
Is NCT06673017 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies PTM-101 for pancreatic ductal adenocarcinoma.
Treatment: PTM-101 — This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
No prior chemo-, radio-, or surgical therapy for PDAC
Cannot have received: radiation therapy
No prior chemo-, radio-, or surgical therapy for PDAC
Cannot have received: surgery
No prior chemo-, radio-, or surgical therapy for PDAC
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Hoag Memorial Hospital Presbyterian · Newport Beach, California
- Karmanos Cancer Institute · Detroit, Michigan
- Northwell Health Zuckerberg Cancer Center · Lake Success, New York
- University of Texas Southwestern Medical Center · Dallas, Texas
- The University of Texas MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06673017 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages